Skip to main content

Table 1 Overview of participation of brothers A and B in familial Alzheimer’s disease study

From: Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study

  Year Brother A Brother B
Baseline 1995 NPA, MRI, CSF NPA, CSF
+  1 year 1996 FDG-PET FDG-PET
+  2 years 1997 NPA, MRI NPA
+  3 years 1998 FDG-PET FDG-PET
+  6 years 2001 NPA, MRI NPA
+  11 years 2006 NPA, MRI, CSF, FDG-PET NPA, CSF, FDG-PET
+  12 years 2007 Interview  
+  13 years 2008 NPA, FDG-PET, PiB-PET  
+  14 years 2009 NPA, MRI, FDG-PET, PiB-PET NPA, MRI, FDG-PET, PiB-PET
+  16 years 2011   NPA
+  17 years 2012   PiB-PET
+  18 years 2013   NPA
+  20 years 2015 Interview, MMSE Interview, MMSE
+  22 years 2017   NPA
  1. Abbreviations: CSF Cerebrospinal fluid sampling, FDG-PET [18F]fluorodeoxyglucose PET, MMSE Mini Mental State Examination, MRI Magnetic resonance imaging, NPA Neuropsychological assessment, PiB-PET [11C]Pittsburgh compound B positron emission tomography, MRI Magnetic resonance imaging
  2. The rows in the table indicate the year in which different examinations were performed. Brother A was diagnosed with mild cognitive impairment in 2006 and with dementia due to Alzheimer’s disease in 2007 (based on clinical symptoms)